Triazavirin to Be Tested for Effectiveness Against Tick-Borne Encephalitis

Triazavirin was developed by scientists of the Ural Federal University and the Ural Branch of the Russian Academy of Sciences.
Credit: UrFU Press Service

The scientific community has provided research recommendations

The Medsintez plant, the manufacturer of the antiviral drug Triazavirin, plans to conduct studies of the drug for effectiveness against tick-borne encephalitis. Aleksandr Petrov, Chairman of the Board of Directors of the Medsintez Plant LLC, notes that the company has already received recommendations from the scientific community. This was reported by TASS.

"The effectiveness of Triazavirin against tick-borne encephalitis is a very interesting topic to study. Scientists are already saying that the drug can be effective against this virus. Currently we are guided by the opinion of scientists, that is why we are considering the possibility of conducting such studies," said Petrov.

He stressed that this year in some regions there is a high activity of ticks and increased detection of cases of encephalitis, that is why Triazavirin research in this area is relevant.

Reference:
Medsintez plant is located in Novouralsk (Sverdlovsk region). It specializes in the production of pharmaceutical products. The plant produces infusion solutions, ready forms of genetically engineered human insulin, solid and liquid forms of drugs. The plant manufactures licensed products and is engaged in the creation of new drugs.

Source/Credit: Ural Federal University

phar080122_01